The role of apoptosis-related genes in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 4, Issue 3, 2002, Pages 174-182

  Fokkema, Eelco ^a   Groen, Harry J M ^a   Meijer, Coby ^a   Timens, Wim ^a   de Jong, Steven ^a   de Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bcl 2; Drug resistance; Epidermal growth factor receptor; Fas; p21; p53; Retinoblastoma; Tumor necrosis factor; Tumor suppressor genes

Indexed keywords

ALPHA TOCOPHEROL; ALPHA2 INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CASPASE; CERAMIDE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FAS LIGAND; GAMMA INTERFERON; LIGAND; METHOTREXATE; NAVELBINE; ONYX 015; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; DRUG TARGETING; GENE MUTATION; GENETIC DISORDER; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN FAMILY; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0036868676     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.025     Document Type: Review

References (150)

1. Hansen H.H. Is there a role for chemotherapy of non-small cell lung cancer? Ann Oncol 1995; 6(suppl 1):79-82.
2. Klastersky J. Therapy of non-small Cell lung cancer. Lung Cancer 1995; 12(suppl 1)S133-S145.
3. Haura E.B. To treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001; 8:326-336.
4. Dancey L, Le Chevalier T. Non-small cell lung cancer: in overview of current management. Eur J Cancer 1997; 33(suppl 1):S2-S7.
5. Schiller JH, Harlington D. Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell Lung cancer. N Eng J Med 2002; 346:92-98.
6. Sandler AB. Current management of small cell lung cancer. Semin Oncol 1997; 24:463-476.
7. Adjei AA. Management of small cell cancer of the lung. Curr Opin Pulm Med 2000; 6:384-390.
8. Johnson DH. Management of small cell lung cancer: current state of the art. Chest 1999; 116(suppl 6):S525-530.
9. Bonomi P, Gale M, Rowland K, et al. Pre-treatment prognostic factors in stage III nonsmall Cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 1991; 20:247-252.
10. Harpole DH, Jr., Hendon JE, 2nd, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55:51-56.
11. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001; 31:43-56.
12. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143:199-210.
13. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 1996; 78:1203-1210.
14. Matsuzoe D, Hideshima T, Kimura A, et al. p53 mutations predict non-small cell lung carcinoma response to radiotherapy. Cancer Lett 1999; 135:189-194.
15. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8:746-759.
16. Esposito V, Baldi A, De Luca A, et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 1997; 28:233-237.
17. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 1996; 178:53-58.
18. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of 53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995; 76:2457-2463.
19. Dosaka-Akita H, Hu SX, Fujino M, et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997; 79: 1329-1337.
20. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52:4828-4831.
21. Harpole DH, Jr., Marks JR, Richards WG, et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1995; 1:659-664.
22. MacKinnon M, Kerr KM, King G, et al. p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg 1997; 11:838-842.
23. Pastorino, U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis.J Clin Oncol 1997; 15:2858-2865.
24. XU HJ, Cagle PT, Hu SX, et al. Altered retinoblastoma and p53 protein status in nonsmall cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996; 2:1169-1176.
25. Apolinario RM, van der Valk F, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15:2456-2466.
26. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996; 14:497-502.
27. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75:1295-1301.
28. Kwa HB, Verheijen MG, Livinov SV, et al. Prognostic factors in resected non-small cell lung cancer: an immunohistochemical study of 39 cases. Lung Cancer 1996; 16:35-45.
29. Kwa HB, Michalides RJ, Dijkman JH, et al. The prognostic Value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer 1996; 14:207-217.
30. McLaren R, Kuzu I, Dunnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992; 66:735-738.
31. Passlick B, Izbicki JR, Haussinger K, et al. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109:1205-1211.
32. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997; 3:1831-1835.
33. Shih CM, Lin PT, Wang HC, et al. Lack of evidence of association of p21 WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 2000; 91:9-15.
34. Xu HJ, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994; 86:695-699.
35. Higashiyama M, Doi O, Kodama K, et al. bcl-2 oncoprotein in surgically resected nonsmall cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997; 64:48-54.
36. Ritter JH, Dresler CM, Wick MR. Expression of bcl-2 protein in stage TIN0M0 nonsmall cell lung carcinoma. Hum Pathol 1995; 26:1227-1232.
37. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71:1003-1007.
38. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329:690-694.
39. Ishida H, Irie K, Itoh T, et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997; 80:1034-1045.
40. Dosaka-Akita H, Katabami M, Hommura H, et al. Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 1999; 56:259-264.
41. Fleming MV, Guinee DG, Jr., Chu WS, et al. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol 1998; 29:60-64.
42. Borner MM, Brousset P, Pfanner-Meyer B, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999; 79:952-958.
43. Cox G, Louise Jones J, Andi A, et al. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001; 34:417-426.
44. Ohsaki Y, Toyoshima E, Fujiuchi S, et al. bcl-2 and p53 protein expression ill nonsmall cell lung cancers: correlation with survival time. Clin Cancer Res 1996; 2:915-920.
45. Anton RC, Brown RW, Younes M, et al. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases. Hum Pathol 1997; 28:1079-1082.
46. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13:1009-1022.
47. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-708.
48. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
49. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1998; 16:1207-1217.
50. Hall PA, Lane DF. p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J Patbol 1994; 172:1-4.
51. Mitsudomi T, Oyama T, Nishida K, et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 1995; 6(suppl 3):S9-S13.
52. Carbone DP, Mitsudomi T, Chiba I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994; 106(suppl 6):S377-S381.
53. Melhem MF, Law JC, el-Ashmawy L, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995; 146:1170-1177.
54. Ebina M, Steinberg SM, Mulshine JL, et al. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of nonsmall cell lung cancer. Cancer Res 1994; 54:2496-2503.
55. Rosell R, Gonzalez-Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995; 22:12-18.
56. Langendijk JA, Thunnissen FB, Lamers RJ, et al. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 1995; 36:218-224.
57. Nishizaki M, Meyn RE, Levy LB, et al. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 2001; 7:2887-2897.
58. Kawabe S, Munshi A, Zumstein LA, et al. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int J Radiat Biol 2001; 77:185-194.
59. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54:2287-2291.
60. Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000; 118:966-970.
61. Roth JA, Grammer SF, Swisher SG, et al. Gene therapy approaches for the management of non-small cell lung cancer. Semin Oncol 2001; 28:50-56.
62. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell king cancer. J Natl Cancer Inst 1999; 91:763-771.
63. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-991.
64. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18:609-622.
65. Schuler M, Herrmann R, De Greve JL, et al. Actenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19:1750-1758.
66. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made front lung cancer patients. Cancer Res 2000; 60:1009-1013.
67. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-298.
68. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 Mutant rumors with ONYX-015, an E1 B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60:6359-6366.
69. Lamont JP, Nemunaitis J, Kuhn JA, et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7:588-592.
70. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and rieck cancer. Nat Med 2000; 6:879-885.
71. HunterT. Braking the cycle. Cell 1993; 75:839-841.
72. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75:805-816.
73. Natsugoe S, Nakashima S, Matsumoto M, et al. Expression of p21 WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999; 5:2445-2449.
74. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP) cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 1999; 17:3150-3159.
75. Palazzo JP, Kafka NJ, Grasso L, et al. The role of p53, p21 WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997; 28:1189-1195.
76. Leonhardt EA, Trinh M, Forrester HB, et al. Persistent decrease in viability as a function of X irradiation of human bladder carcinoma cells in G1 or S phase. Radiat Res 1998; 149:343-349.
77. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2:1591-1599.
78. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74:529-534.
79. Vonlanthen S, Heighway J, Kappeler A, et al. p21 is associated with cyclin DI, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 2000; 16:951-957.
80. Takeshima Y, Yamasaki M, Nishisaka T, et al. p21 WAF1/CIP1 expression in primary lung adenocarcinomas: heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities. Carcinogenesis 1998; 19:1755-1761.
81. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993; 8:1913-1919.
82. Xu HJ, Hu SX, Cagle PT, et al. Absence of retinoblastoma protein expression in Primary non-small cell lung carcinomas. Cancer Res 1991; 51:2735-2739.
83. Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage nonsmall cell lung cancer and its clinical implication. Cancer Res 2000; 60:4000-4004.
84. Bowen C, Spiegel S, Gelmann EP. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 1998; 58:3275-3281.
85. Claudio PP, Howard CM, Pacilio C, et al. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 2000; 60:372-382.
86. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-619.
87. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human hax gene. Cell 1995; 80:293-299.
88. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 qnd bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805.
89. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22:181-190.
90. Groeger AM, Caputi M, Esposito V, et al. Bcl-2 protein expression correlates with nodal status in non small Cell lung cancer. Anticancer Res 1999; 19:821-824.
91. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76:935-938.
92. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4:1609-1618.
93. Caputi M, Groeger AM, Esposito V, et al. Frequent high expression of bax proapoptotic protein in non-small cell lung cancer. Anticancer Res 1999; 19:825-827.
94. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149:1941-1952.
95. Pearson AS, Spitz FR, Swisher SG, et al. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 2000; 6:887-890.
96. Kagawa S, Pearson SA, Ji L, et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene has. Gene Ther 2000; 7:75-79.
97. Leech SH, Olie RA, Gautschi O, et al. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 2000; 86:570-576.
98. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76:959-962.
99. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992; 267:10709-10715.
100. Itoh N, Yonchara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-243.
101. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378-3404.
102. Nagata S. Apoptosis by death factor. Cell 1997; 88:355-365.
103. Giaccone G, Johnson DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002; 13:2 (Abstract #40).
104. Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13:127 (Abstract #4680).
105. Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol 2002; 196:125-134
106. Nichans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57:1007-1012.
107. Hellquist HB, Olejnicka B, Jadner M, et al. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Br J Cancer 1997; 76:175-179.
108. Uramoto H, Osaki T, Inoue M, et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 1999; 35:1462-1465.
109. Lee SH, Shin MS, Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in nonsmall cell lung cancer. Oncogene 1999; 18:3754-3760.
110. Boldrini L, Faviana P, Pistolesi F, et al. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene 2001; 20:6632-6637.
111. Friesen C, Heir I, Krammer PH, et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574-577.
112. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.J Clin Invest 1997; 99:403-413.
113. Fulda S, Los M, Friesen C, et al. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998; 76:105-114.
114. Friesen C, Fulda S, Debarin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997; 11:1833-1841.
115. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997; 89:957-964.
116. Weller M, Frei K, Groscurth P, et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.J Clin Invest 1994; 94:954-964.
117. Xu X, Fu XY, Plate J, et al. IFN-gamnia induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL, expression. Cancer Res 1998; 58:2832-2837.
118. Keane MM, Ettenberg SA, Lowrey GA, et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56:4791-4798.
119. Weller M, Malipiero U, Aguzzi A, et al. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95:2633-2643.
120. Yu W, Israel K, Liao QY, et al. Vitamin E succinate VES) induces Fis sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res 1999; 59:953-961.
121. Giardina C, Boulares H, Inan MS. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim Biophys Acta 1999; 1448:425-438.
122. Weller M, Malipiero U, Rensing-Ehl A, et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995; 55:2936-2944.
123. Jaattela M, Benedict M, Tewari M, et al. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995; 10:2297-2305.
124. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation, Science 1998; 281:1305-1308.
125. Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61:1645-1651.
126. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163.
127. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-162.
128. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-385.
129. the Jong S, Spierings D, Timens W, et al. High expression levels of the trail receptor DR4 in non-small cell lung cancer. Proc Am Assoc Cancer Res 2001; 42:15 (Abstract #1709).
130. Wu WG, Soria JC, Wang L, et al. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 2000; 20:4525-4529.
131. Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 1999; 15:793-802.
132. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61:3330-3338.
133. Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999; 59:5683-5686.
134. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-retated apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Common 2001; 280:788-797.
135. de Jong S, Timmer T, Heijenbrok FJ, et al. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001; 20:51-56.
136. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(suppl 18):S32-S40.
137. Barbender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001; 7:1850-1855.
138. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-S15.
139. O'Byrne KJ, Cox G, Swinson D, et al. Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 2001; 34(suppl 2):S83-S89.
140. Reinmuth N, Brandt B, Kunze WP, et al. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000; 16:991-996.
141. Sabel MS, Yamada M, Kawaguchi Y, et al. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 2000; 49:101-108.
142. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7:603-607.
143. Pfeiffer P, Next E, Bentzen SM, et al. Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis. Br J Cancer 1998; 78:96-99.
144. Pfeiffer, P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein pI85HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74:86-91.
145. Giatromanolaki A, Koukourakis MI, O'Byrne K, et al. Non-small cell lung cancer: cerbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996; 16:3819-3825.
146. Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000; 60 (suppl 1):S33-S40.
147. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
148. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001; 12(suppl 1):S81-S87.
149. Baselga J, Yano S, Giaccone G, et al. Initial results from a phase II trial of ZD1839 (Iressa) as second- and thrid-line monotherapy for patients with advanced non-small cell lung cancer (IDEAL 1). Proceedings of the AACR-NCI-EORTC International Conference. 2001:(Abstract #630A).
150. Lei W, Mayotte JE, Levitt ML. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small Cell lung cancer cells. Anticancer Res 1999; 19:221-228.